FY2026 EPS Estimates for Astrazeneca Cut by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Erste Group Bank lowered their FY2026 EPS estimates for shares of Astrazeneca in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $10.25 per share for the year, down from their prior estimate of $10.33. The consensus estimate for Astrazeneca’s current full-year earnings is $10.22 per share.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. During the same quarter last year, the firm earned $2.17 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis.

Several other research analysts have also commented on the company. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Weiss Ratings cut shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. HSBC lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Astrazeneca Stock Performance

NYSE AZN opened at $161.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. The stock’s fifty day moving average is $175.98 and its two-hundred day moving average is $186.98. The firm has a market capitalization of $250.94 billion, a P/E ratio of 24.19, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. Astrazeneca has a fifty-two week low of $145.79 and a fifty-two week high of $212.71.

Hedge Funds Weigh In On Astrazeneca

Hedge funds have recently bought and sold shares of the company. IHT Wealth Management LLC increased its stake in Astrazeneca by 0.3% during the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares during the period. Visionary Wealth Advisors grew its stake in shares of Astrazeneca by 1.5% in the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after acquiring an additional 60 shares in the last quarter. Vista Investment Management grew its stake in shares of Astrazeneca by 0.3% in the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after acquiring an additional 60 shares in the last quarter. Kestra Investment Management LLC increased its position in shares of Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC increased its position in shares of Astrazeneca by 4.3% during the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.